Has Jai Radhakrishnan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $369,304 in general payments to Jai Radhakrishnan, MD across 217 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jai Radhakrishnan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jai Radhakrishnan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jai Radhakrishnan, MD

Nephrology · New York, NYNPI 1275605446

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $274,388 of the $369,304 with a category attached, or 74.3%. It is spread thinly across 27 manufacturers, the largest accounting for just 20.3%. 2025 is the largest year on record at $149,354, more than ten times the $2,500 reported in 2019. Among nephrology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$369,304in general payments, 2019–2025

Across 217 payments — averaging $1701.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$75K
GSK$52K
Novartis$44K
AstraZeneca$37K
Otsuka Pharmaceutical Development & Commercialization, Inc.$37K
Travere Therapeutics, Inc.$26K
plus $98K from 21 others

$658,475in research payments, 2019–2025

Across 181 payments — averaging $3637.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Travere Therapeutics, Inc.$329K
Bayer$106K
Boston Scientific$103K
Vertex$67K
Novartis$28K
Otsuka Pharmaceutical Development & Commercialization, Inc.$21K
plus $5K from 1 others

What the payments were for

Consulting fees$274,38874%
Speaking & faculty fees$85,76423%
Travel & lodging$6,1282%
Food & beverage$3,0241%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	44	$75,134
GSK	23	$52,172
Novartis	16	$43,801
AstraZeneca(2 entities)	23	$37,252
Otsuka Pharmaceutical Development & Commercialization, Inc.	18	$37,071
Travere Therapeutics, Inc.	22	$26,106
Boehringer Ingelheim International GmbH	15	$13,579
Sanofi	9	$12,957
Apellis Pharmaceuticals, Inc.	6	$11,918
ANI Pharmaceuticals, Inc.	6	$11,462
Calliditas Therapeutics US Inc.	3	$10,503
Beone Medicines USA, Inc.	2	$5,565
Sanofi US Services Inc.	4	$5,220
Beigene USA, Inc.	2	$5,215
Novartis Pharma AG	2	$4,525
Otsuka America Pharmaceutical, Inc.	7	$3,777
Vertex	3	$3,296
Mallinckrodt Hospital Products Inc.	2	$3,212
Philips North America LLC	2	$1,440
Akebia Therapeutics Inc	1	$1,250
Aurinia Pharma U.S., Inc.	1	$1,200
Sanofi-aventis U.S. LLC	1	$1,142
Biocryst Pharmaceuticals, Inc.	1	$956
Johnson & Johnson	1	$375
Biogen	1	$133
Si-bone, Inc.	1	$26
Novo Nordisk	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BENLYSTA$51,233
PURIFIED CORTROPHIN GEL$11,382
BRUKINSA$10,780
TARPEYO$10,500
CABLIVI$5,628
Tavneos$4,928
Fabhalta$4,800
UPLIZNA$3,942
SAMSCA$2,500
(9520) IGT Devices Undivided$1,440
AURYXIA$1,250

How this compares

$369,304 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York →

Medicare billing

Part B allowed, 2024

$160,130

Medicare patients

293

Services billed

1,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VelphoroSucroferric Oxyhydroxide	13	$39,084
JardianceEmpagliflozin	11	$6,611
Atorvastatin Calcium	16	$395
Famotidine	17	$228
Amlodipine Besylate	26	$188
Losartan Potassium	15	$114

Paid to pharmacies, not to this prescriber.

Other nephrology in New York

Gerald AppelNew York$842K
Richard ChanNew York$514K
Steven CocaNew York$445K
Girish NadkarniNew York$281K
James ChevalierNew York$202K
David CharytanNew York$164K
Kirk CampbellNew York$152K
Andrew BombackNew York$106K
Alan PerlmanNew York$101K
Phyllis AugustNew York$97K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →